Medication only improves limb movements while deep brain stimulation improves eye and limb movements during visually-guided reaching in Parkinson's disease.

Autor:	Munoz MJ; Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, United States., Arora R; Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, United States.; USF Health Morsani College of Medicine, University of South Florida, Tampa, FL, United States., Rivera YM; Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, United States., Drane QH; Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, United States., Pal GD; Department of Neurology, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ, United States.; Department of Neurological Sciences, Section of Parkinson Disease and Movement Disorders, Rush University Medical Center, Chicago, IL, United States., Verhagen Metman L; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Sani SB; Department of Neurosurgery, Rush University Medical Center, Chicago, IL, United States., Rosenow JM; Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Goelz LC; Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, United States., Corcos DM; Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, United States., David FJ; Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, IL, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in human neuroscience [Front Hum Neurosci] 2023 Oct 02; Vol. 17, pp. 1224611. Date of Electronic Publication: 2023 Oct 02 (Print Publication: 2023).
DOI:	10.3389/fnhum.2023.1224611
Abstrakt:	Background: Antiparkinson medication and subthalamic nucleus deep brain stimulation (STN-DBS), two common treatments of Parkinson's disease (PD), effectively improve skeletomotor movements. However, evidence suggests that these treatments may have differential effects on eye and limb movements, although both movement types are controlled through the parallel basal ganglia loops. Objective: Using a task that requires both eye and upper limb movements, we aimed to determine the effects of medication and STN-DBS on eye and upper limb movement performance. Methods: Participants performed a visually-guided reaching task. We collected eye and upper limb movement data from participants with PD who were tested both OFF and ON medication ( n = 34) or both OFF and ON bilateral STN-DBS while OFF medication ( n = 11). We also collected data from older adult healthy controls ( n = 14). Results: We found that medication increased saccade latency, while having no effect on reach reaction time (RT). Medication significantly decreased saccade peak velocity, while increasing reach peak velocity. We also found that bilateral STN-DBS significantly decreased saccade latency while having no effect on reach RT, and increased saccade and reach peak velocity. Finally, we found that there was a positive relationship between saccade latency and reach RT, which was unaffected by either treatment. Conclusion: These findings show that medication worsens saccade performance and benefits reaching performance, while STN-DBS benefits both saccade and reaching performance. We explore what the differential beneficial and detrimental effects on eye and limb movements suggest about the potential physiological changes occurring due to treatment. Competing Interests: GP received grant support from National Institute of Neurological Disorders and Stroke, and consulting fees from Guidepoint, Kyowa Kirin. LV receives research support from NIH; receives research support, is on the advisory board of, and consults for Abbott, AbbVie, and Avion; receives research support from and consults for Boston Scientific; receives research support from and is on the advisory board for Biogen; and receives research support from Medtronic, Neuroderm, and Prilenia Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Munoz, Arora, Rivera, Drane, Pal, Verhagen Metman, Sani, Rosenow, Goelz, Corcos and David.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu